17
Mar

Amgen’s promising cardio drug aced its 6th late-stage study, the company said, beating out statins in patients with a cholesterol-boosting genetic disorder and widening the drugmaker’s lead in a potentially lucrative new field.

…read more

Source: Amgen goes 6-for-6 in Phase III, leading the race for a new cardio blockbuster

    

0 No comments